The U.S. Supreme Court agreed to hear an appeal by Teva Pharmaceutical Industries Ltd. to revive a patent that would protect Copaxone® from generic rivals until September 2015. Without that patent, Teva would lose legal protection on Copaxone this May.
With this latest development, a company that begins selling a generic Copaxone in May might eventually have to pay Teva for lost sales if the Supreme Court rules in Teva's favor. Such a decision might not come until June 2015.
The current justices have taken greater interest in patent laws, and Teva's appeal could have impact beyond its industry, according to analysts.